PL3448848T3 - Postać polimorficzna N-{6-(2-hydroksypropan-2-ylo)-2-[2-(metylosulfonylo)etylo]-2H-indazol-5-ilo}-6-(trifluorometylo)pirydyno-2-karboksyamidu - Google Patents

Postać polimorficzna N-{6-(2-hydroksypropan-2-ylo)-2-[2-(metylosulfonylo)etylo]-2H-indazol-5-ilo}-6-(trifluorometylo)pirydyno-2-karboksyamidu

Info

Publication number: PL3448848T3
Authority: PL; Poland
Prior art keywords: methylsulphonyl; hydroxypropan; indazol; carboxamide; trifluoromethyl
Prior art date: 2016-04-29

Application number

PL17718560.0T

Other languages

English (en)

Inventor

Tobias THALER

Johannes Platzek

Nicolas GUIMOND

Original Assignee

Bayer Pharma Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-29

Filing date

2017-04-25

Publication date

2024-03-11

2017-04-25 Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft

2024-03-11 Publication of PL3448848T3 publication Critical patent/PL3448848T3/pl

Links

OQAMEEFUUFJZRS-UHFFFAOYSA-N N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound OC(C)(C)C=1C(=CC2=CN(N=C2C=1)CCS(=O)(=O)C)NC(=O)C1=NC(=CC=C1)C(F)(F)F OQAMEEFUUFJZRS-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

PL17718560.0T 2016-04-29 2017-04-25 Postać polimorficzna N-{6-(2-hydroksypropan-2-ylo)-2-[2-(metylosulfonylo)etylo]-2H-indazol-5-ilo}-6-(trifluorometylo)pirydyno-2-karboksyamidu PL3448848T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16167652		2016-04-29
PCT/EP2017/059767 WO2017186703A1 (en)	2016-04-29	2017-04-25	Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide

Publications (1)

Publication Number	Publication Date
PL3448848T3 true PL3448848T3 (pl)	2024-03-11

Family

ID=55860769

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL17718560.0T PL3448848T3 (pl)	2016-04-29	2017-04-25	Postać polimorficzna N-{6-(2-hydroksypropan-2-ylo)-2-[2-(metylosulfonylo)etylo]-2H-indazol-5-ilo}-6-(trifluorometylo)pirydyno-2-karboksyamidu
PL17718558T PL3448846T3 (pl)	2016-04-29	2017-04-25	Synteza indazoli

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL17718558T PL3448846T3 (pl)	2016-04-29	2017-04-25	Synteza indazoli

Country Status (43)

Country	Link
US (2)	US10501417B2 (pl)
EP (4)	EP4275754A3 (pl)
JP (2)	JP7068188B2 (pl)
KR (2)	KR102373220B1 (pl)
CN (3)	CN113185457A (pl)
AR (1)	AR108245A1 (pl)
AU (2)	AU2017256626B2 (pl)
BR (2)	BR112018072246A2 (pl)
CA (2)	CA3022332A1 (pl)
CL (2)	CL2018003087A1 (pl)
CO (2)	CO2018011622A2 (pl)
CU (1)	CU20180131A7 (pl)
DK (2)	DK3448848T3 (pl)
DO (1)	DOP2018000237A (pl)
EA (2)	EA038035B1 (pl)
EC (1)	ECSP18081437A (pl)
ES (2)	ES2966772T3 (pl)
FI (1)	FI3448848T3 (pl)
GE (1)	GEP20217214B (pl)
HR (2)	HRP20231454T1 (pl)
HU (2)	HUE056460T2 (pl)
IL (2)	IL262414B2 (pl)
JO (2)	JOP20170099B1 (pl)
LT (2)	LT3448848T (pl)
MA (1)	MA44759B1 (pl)
MX (2)	MX2018013235A (pl)
MY (2)	MY187184A (pl)
NI (1)	NI201800112A (pl)
PE (1)	PE20190107A1 (pl)
PH (1)	PH12018502289A1 (pl)
PL (2)	PL3448848T3 (pl)
PT (2)	PT3448846T (pl)
RS (2)	RS62112B1 (pl)
SA (1)	SA518400333B1 (pl)
SG (2)	SG11201808108XA (pl)
SI (2)	SI3448846T1 (pl)
SV (1)	SV2018005775A (pl)
TN (1)	TN2018000352A1 (pl)
TW (2)	TWI657084B (pl)
UA (2)	UA124103C2 (pl)
UY (2)	UY37216A (pl)
WO (2)	WO2017186689A1 (pl)
ZA (1)	ZA201808057B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3705B1 (ar)	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CA3016364A1 (en)	2016-03-03	2017-09-08	Bayer Pharma Aktiengesellschaft	New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
CN109071491B (zh)	2016-04-29	2020-08-21	拜耳医药股份有限公司	吲唑的合成
MX2018013235A (es) *	2016-04-29	2019-02-13	Bayer Pharma AG	Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida.
KR102547834B1 (ko) *	2016-06-01	2023-06-26	바이엘 애니멀 헬스 게엠베하	동물에서의 알레르기성 및/또는 염증성 질환의 치료 및 예방에 유용한 치환된 인다졸
BR112018074919A2 (pt)	2016-06-01	2020-11-03	Bayer Pharma Aktiengesellschaft	uso de indazóis 2-substituídos para tratamento e profilaxia de doenças autoimunes.
JOP20180011A1 (ar)	2017-02-16	2019-01-30	Gilead Sciences Inc	مشتقات بيرولو [1، 2-b]بيريدازين
KR20210024543A (ko)	2018-06-25	2021-03-05	치아타이 티안큉 파마수티컬 그룹 주식회사	IRAK4 억제제로서의 이소티아졸로[5,4-d]피리미딘 화합물
TWI721483B (zh)	2018-07-13	2021-03-11	美商基利科學股份有限公司	吡咯并[1,2-b]嗒𠯤衍生物
CN110981903A (zh) *	2019-11-28	2020-04-10	南京正济医药研究有限公司	一种艾日布林中间体化合物提高光学纯度的精制方法
US10894812B1 (en)	2020-09-30	2021-01-19	Alpine Roads, Inc.	Recombinant milk proteins
CA3191387A1 (en)	2020-09-30	2022-04-07	Nobell Foods, Inc.	Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en)	2020-09-30	2021-03-16	Alpine Roads, Inc.	Recombinant fusion proteins for producing milk proteins in plants
CN114469979B (zh) *	2021-12-15	2024-04-09	安徽贝克生物制药有限公司	一种核糖核苷类似物的药物组合物、吸入剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7163937B2 (en)	2003-08-21	2007-01-16	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
US20100048660A1 (en)	2006-02-10	2010-02-25	Graham Michael Wynne	Treatment of duchenne muscular dystrophy
JP5258563B2 (ja)	2006-06-29	2013-08-07	日産化学工業株式会社	αアミノ酸誘導体及びそれを有効成分として含む医薬
CA2663100A1 (en)	2006-09-07	2008-03-13	Biogen Idec Ma Inc.	Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
US20120196824A1 (en)	2009-10-09	2012-08-02	Mitsubishi Tanabe Pharma Corporation	Therapeutic agent for cerebral infarction
WO2011153588A1 (en)	2010-06-10	2011-12-15	Biota Scientific Management Pty Ltd	Viral polymerase inhibitors
US9073892B2 (en)	2010-12-20	2015-07-07	Merck Serono S.A.	Indazolyl triazol derivatives
WO2013106254A1 (en)	2012-01-11	2013-07-18	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US9126984B2 (en) *	2013-11-08	2015-09-08	Iteos Therapeutics	4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
EP3066090A1 (en)	2013-11-08	2016-09-14	iTeos Therapeutics	4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) *	2013-12-19	2019-08-01	德商拜耳製藥公司	新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
SG11201605408RA (en) *	2014-01-10	2016-07-28	Aurigene Discovery Tech Ltd	Indazole compounds as irak4 inhibitors
JO3705B1 (ar) *	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en)	2015-04-30	2016-11-03	Bayer Pharma Aktiengesellschaft	Combinations of inhibitors of irak4 with inhibitors of btk
BR112018000624A2 (pt)	2015-07-15	2018-09-18	Aurigene Discovery Technologies Limited	compostos de indazol e azaindazol como inibidores de irak-4
CA3016364A1 (en)	2016-03-03	2017-09-08	Bayer Pharma Aktiengesellschaft	New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) *	2016-03-17	2017-09-20	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib
CN109071491B (zh)	2016-04-29	2020-08-21	拜耳医药股份有限公司	吲唑的合成
MX2018013235A (es)	2016-04-29	2019-02-13	Bayer Pharma AG	Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida.
KR102547834B1 (ko)	2016-06-01	2023-06-26	바이엘 애니멀 헬스 게엠베하	동물에서의 알레르기성 및/또는 염증성 질환의 치료 및 예방에 유용한 치환된 인다졸
BR112018074919A2 (pt)	2016-06-01	2020-11-03	Bayer Pharma Aktiengesellschaft	uso de indazóis 2-substituídos para tratamento e profilaxia de doenças autoimunes.

2017
- 2017-04-25 MX MX2018013235A patent/MX2018013235A/es unknown
- 2017-04-25 MY MYPI2018703968A patent/MY187184A/en unknown
- 2017-04-25 KR KR1020187030698A patent/KR102373220B1/ko active IP Right Grant
- 2017-04-25 SG SG11201808108XA patent/SG11201808108XA/en unknown
- 2017-04-25 PT PT177185584T patent/PT3448846T/pt unknown
- 2017-04-25 UA UAA201811516A patent/UA124103C2/uk unknown
- 2017-04-25 BR BR112018072246-4A patent/BR112018072246A2/pt active IP Right Grant
- 2017-04-25 US US16/097,065 patent/US10501417B2/en active Active
- 2017-04-25 SI SI201730851T patent/SI3448846T1/sl unknown
- 2017-04-25 AU AU2017256626A patent/AU2017256626B2/en active Active
- 2017-04-25 MX MX2018013234A patent/MX2018013234A/es unknown
- 2017-04-25 JP JP2018556409A patent/JP7068188B2/ja active Active
- 2017-04-25 SG SG11201808566WA patent/SG11201808566WA/en unknown
- 2017-04-25 TN TNP/2018/000352A patent/TN2018000352A1/en unknown
- 2017-04-25 PL PL17718560.0T patent/PL3448848T3/pl unknown
- 2017-04-25 RS RS20210898A patent/RS62112B1/sr unknown
- 2017-04-25 ES ES17718560T patent/ES2966772T3/es active Active
- 2017-04-25 EP EP23189176.3A patent/EP4275754A3/en not_active Ceased
- 2017-04-25 DK DK17718560.0T patent/DK3448848T3/da active
- 2017-04-25 RS RS20231171A patent/RS64928B1/sr unknown
- 2017-04-25 WO PCT/EP2017/059744 patent/WO2017186689A1/en active Application Filing
- 2017-04-25 HU HUE17718558A patent/HUE056460T2/hu unknown
- 2017-04-25 ES ES17718558T patent/ES2883298T3/es active Active
- 2017-04-25 IL IL262414A patent/IL262414B2/en unknown
- 2017-04-25 DK DK17718558.4T patent/DK3448846T3/da active
- 2017-04-25 AU AU2017257211A patent/AU2017257211B2/en active Active
- 2017-04-25 GE GEAP201714933A patent/GEP20217214B/en unknown
- 2017-04-25 FI FIEP17718560.0T patent/FI3448848T3/fi active
- 2017-04-25 CU CU2018000131A patent/CU20180131A7/es unknown
- 2017-04-25 UA UAA201811329A patent/UA123169C2/uk unknown
- 2017-04-25 CN CN202110343286.3A patent/CN113185457A/zh active Pending
- 2017-04-25 LT LTEPPCT/EP2017/059767T patent/LT3448848T/lt unknown
- 2017-04-25 KR KR1020187030699A patent/KR102373017B1/ko active IP Right Grant
- 2017-04-25 SI SI201731443T patent/SI3448848T1/sl unknown
- 2017-04-25 HU HUE17718560A patent/HUE064389T2/hu unknown
- 2017-04-25 EP EP23189520.2A patent/EP4275755A3/en active Pending
- 2017-04-25 EP EP17718558.4A patent/EP3448846B1/en active Active
- 2017-04-25 MA MA44759A patent/MA44759B1/fr unknown
- 2017-04-25 BR BR112018072242-1A patent/BR112018072242A2/pt active Search and Examination
- 2017-04-25 LT LTEP17718558.4T patent/LT3448846T/lt unknown
- 2017-04-25 CA CA3022332A patent/CA3022332A1/en active Pending
- 2017-04-25 US US16/097,067 patent/US10759758B2/en active Active
- 2017-04-25 PT PT177185600T patent/PT3448848T/pt unknown
- 2017-04-25 EP EP17718560.0A patent/EP3448848B1/en active Active
- 2017-04-25 EA EA201892430A patent/EA038035B1/ru unknown
- 2017-04-25 CN CN201780026130.4A patent/CN109071489B/zh active Active
- 2017-04-25 PL PL17718558T patent/PL3448846T3/pl unknown
- 2017-04-25 MY MYPI2018703965A patent/MY190319A/en unknown
- 2017-04-25 HR HRP20231454TT patent/HRP20231454T1/hr unknown
- 2017-04-25 CA CA3022324A patent/CA3022324A1/en active Pending
- 2017-04-25 PE PE2018002251A patent/PE20190107A1/es unknown
- 2017-04-25 WO PCT/EP2017/059767 patent/WO2017186703A1/en active Application Filing
- 2017-04-25 JP JP2018556408A patent/JP6954924B2/ja active Active
- 2017-04-25 CN CN201780040919.5A patent/CN109415340B/zh active Active
- 2017-04-25 EA EA201892415A patent/EA201892415A1/ru unknown
- 2017-04-27 JO JOP/2017/0099A patent/JOP20170099B1/ar active
- 2017-04-27 JO JOP/2017/0100A patent/JOP20170100B1/ar active
- 2017-04-28 UY UY0001037216A patent/UY37216A/es active IP Right Grant
- 2017-04-28 TW TW106114178A patent/TWI657084B/zh active
- 2017-04-28 AR ARP170101088A patent/AR108245A1/es unknown
- 2017-04-28 UY UY0001037215A patent/UY37215A/es not_active Application Discontinuation
- 2017-04-28 TW TW106114180A patent/TWI649314B/zh active
2018
- 2018-10-26 PH PH12018502289A patent/PH12018502289A1/en unknown
- 2018-10-29 CL CL2018003087A patent/CL2018003087A1/es unknown
- 2018-10-29 CO CONC2018/0011622A patent/CO2018011622A2/es unknown
- 2018-10-29 CL CL2018003088A patent/CL2018003088A1/es unknown
- 2018-10-29 NI NI201800112A patent/NI201800112A/es unknown
- 2018-10-29 IL IL262659A patent/IL262659B/en active IP Right Grant
- 2018-10-29 SA SA518400333A patent/SA518400333B1/ar unknown
- 2018-10-29 CO CONC2018/0011644A patent/CO2018011644A2/es unknown
- 2018-10-29 DO DO2018000237A patent/DOP2018000237A/es unknown
- 2018-10-29 SV SV2018005775A patent/SV2018005775A/es unknown
- 2018-10-29 EC ECSENADI201881437A patent/ECSP18081437A/es unknown
- 2018-11-28 ZA ZA2018/08057A patent/ZA201808057B/en unknown
2021
- 2021-07-06 HR HRP20211072TT patent/HRP20211072T1/hr unknown

Also Published As

Publication number	Publication date
NZ746469A (en)	2023-08-25
EA201892430A1 (ru)	2019-05-31
UA123169C2 (uk)	2021-02-24
MA44759A (fr)	2019-03-06
JP2019514922A (ja)	2019-06-06
HRP20231454T1 (hr)	2024-03-01
EA038035B1 (ru)	2021-06-25
TW201738230A (zh)	2017-11-01
CO2018011622A2 (es)	2018-11-22
AU2017257211B2 (en)	2021-05-27
RS64928B1 (sr)	2023-12-29
WO2017186703A1 (en)	2017-11-02
PE20190107A1 (es)	2019-01-15
KR20180137496A (ko)	2018-12-27
CN109071489A (zh)	2018-12-21
EP3448848B1 (en)	2023-09-27
US10501417B2 (en)	2019-12-10
FI3448848T3 (fi)	2023-12-21
PT3448848T (pt)	2024-01-02
JP6954924B2 (ja)	2021-10-27
AU2017256626A1 (en)	2018-10-11
JP2019514923A (ja)	2019-06-06
NI201800112A (es)	2019-08-29
CN109415340A (zh)	2019-03-01
CL2018003088A1 (es)	2019-01-25
IL262659B (en)	2021-05-31
HUE056460T2 (hu)	2022-02-28
IL262414A (en)	2018-12-31
SI3448848T1 (sl)	2024-01-31
IL262659A (en)	2018-12-31
MY190319A (en)	2022-04-13
CA3022324A1 (en)	2017-11-02
US10759758B2 (en)	2020-09-01
UA124103C2 (uk)	2021-07-21
SV2018005775A (es)	2019-02-07
KR102373220B1 (ko)	2022-03-11
EA201892415A1 (ru)	2019-05-31
TWI649314B (zh)	2019-02-01
TN2018000352A1 (en)	2020-06-15
JP7068188B2 (ja)	2022-05-16
EP4275754A3 (en)	2023-12-27
PL3448846T3 (pl)	2021-12-20
CN109415340B (zh)	2021-10-12
CL2018003087A1 (es)	2019-02-22
AR108245A1 (es)	2018-08-01
CN109071489B (zh)	2020-07-10
HRP20211072T1 (hr)	2021-10-01
MY187184A (en)	2021-09-09
MA44759B1 (fr)	2024-01-31
TW201738232A (zh)	2017-11-01
UY37216A (es)	2018-06-29
ECSP18081437A (es)	2018-11-30
EP4275755A2 (en)	2023-11-15
ES2883298T3 (es)	2021-12-07
MX2018013235A (es)	2019-02-13
US20190112270A1 (en)	2019-04-18
KR20180137497A (ko)	2018-12-27
DOP2018000237A (es)	2018-11-15
AU2017257211A1 (en)	2018-10-11
CN113185457A (zh)	2021-07-30
CA3022332A1 (en)	2017-11-02
SI3448846T1 (sl)	2021-09-30
DK3448848T3 (da)	2023-12-18
IL262414B1 (en)	2023-06-01
EP4275755A3 (en)	2023-12-27
UY37215A (es)	2017-11-30
RS62112B1 (sr)	2021-08-31
BR112018072242A2 (pt)	2019-04-09
EP3448846A1 (en)	2019-03-06
JOP20170100B1 (ar)	2022-03-14
PT3448846T (pt)	2021-08-19
JOP20170099B1 (ar)	2022-03-14
NZ746526A (en)	2023-08-25
CU20180131A7 (es)	2019-06-04
ES2966772T3 (es)	2024-04-24
LT3448848T (lt)	2023-11-27
LT3448846T (lt)	2021-07-26
BR112018072246A2 (pt)	2019-02-12
EP3448846B1 (en)	2021-05-26
GEP20217214B (en)	2021-01-25
KR102373017B1 (ko)	2022-03-11
MX2018013234A (es)	2019-02-13
US20190106407A1 (en)	2019-04-11
PH12018502289B1 (en)	2019-07-15
ZA201808057B (en)	2023-05-31
SA518400333B1 (ar)	2022-06-05
PH12018502289A1 (en)	2019-07-15
CO2018011644A2 (es)	2018-11-13
SG11201808566WA (en)	2018-11-29
DK3448846T3 (da)	2021-08-16
EP3448848A1 (en)	2019-03-06
IL262414B2 (en)	2023-10-01
HUE064389T2 (hu)	2024-03-28
TWI657084B (zh)	2019-04-21
AU2017256626B2 (en)	2021-05-27
SG11201808108XA (en)	2018-10-30
EP4275754A2 (en)	2023-11-15
WO2017186689A1 (en)	2017-11-02

Publication	Publication Date	Title
IL262414A (en)	2018-12-31	A polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulfonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
IL249491A0 (en)	2017-02-28	Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4- Carboxamide
HK1244276A1 (zh)	2018-08-03	用於治療hiv的稠合嘧啶化合物
IL266955B1 (en)	2023-05-01	Polymorphs of spiafatrin and its salts
IL262391B (en)	2022-03-01	Crystal forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-h2-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
ZA201803748B (en)	2019-03-27	4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl) pyridin-3-yl)oxy)benzonitrile and processes of preparation
RS59608B1 (sr)	2020-01-31	Antagonist nk-1/nk-3 receptora za lečenje valunga
HK1249518A1 (zh)	2018-11-02	取代吡啶並嘧啶類化合物的合成工藝
SG11201704431VA (en)	2017-09-28	Novel salt of fused pyrimidine compound and crystal thereof